Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
New Drug CagriSema May Lead to 10% More Weight Loss Than Wegovy or Ozempic
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.
Novo Nordisk maintains booming sales of obesity and diabetes drugs
The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market and Novo Nordisk has faced lower prescriptions of Wegovy than expected.
Novo Nordisk is scheduled to report results for the third quarter on Wednesday. Here is what you need to know: NET PROFIT FORECAST: Net profit in the quarter is expected to rise 19% to 26.79 billion ...
Quartz on MSN1d
A new stronger Ozempic is coming. Here's what to knowNovo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback